SIGA Technologies Inc. (SIGA)

[axelvento]

Dr. Dennis Hruby CSO :For the expanded safety study, we have set up 9 clinical sites around the U.S., and these sites began dosing mid-quarter. I would characterize enrollment as being off to substantial and strong start. As of the end of July, approximately half the study had been enrolled with most enrollees having completed the 28-day dosing period. For the TPOXX plus Jynneos immunogenicity trial, we have 2 sites recruiting and screening volunteers. This trial started in early 2022 and enrollment got off to a slow start.



https://www.stockilluminati.com/siga/display.php?url=https%3a%2f%2fwww.stockilluminati.com%2fsiga%2fsanews.html

$SIGA winner